摘要
目的:探讨罗沙司他联合促红细胞生成素治疗肾性贫血的效果。方法:选取2022年1月—2023年12月本院诊治的血液透析肾性贫血患者99例为研究对象,随机分为罗沙司他组50例与对照组49例。对照组给予促红细胞生成素治疗,罗沙司他组给予罗沙司他联合促红细胞生成素治疗,比较两组不良反应、红细胞计数(RBC)、血细胞比容(Hct)、血清铁蛋白含量、血红蛋白(Hb)达标率、Hb有效率。结果:罗沙司他组高钾血症、恶心呕吐、头晕、腹泻不良反应发生率与对照组比较,差异无统计学意义(P>0.05);罗沙司他组治疗后RBC、Hct、血清铁蛋白含量高于对照组(P<0.05);罗沙司他组治疗2个月后Hb达标率、Hb有效率分别为98.00%、100.00%,高于对照组的85.71%、85.71%,(P<0.05)。结论:罗沙司他联合促红细胞生成素治疗肾性贫血具有很好的安全性,不仅能提高患者的RBC与Hct,还能提高患者的血清铁蛋白含量,改善Hb达标率、Hb有效率。
Objective:To explore the effect of roxostat combined with erythropoietin in the treatment of renal anemia.Method:A total of 99 hemodialysis patients with renal anemia diagnosed and treated in our hospital from January 2022 to December 2023 were selected as the research objects,and randomly divided into roxadustat group(50 patients)and control group(49 patients).The control group was treated with erythropoietin,and the rosastat group was treated with rosastat combined with erythropoietin.The adverse reactions,red blood cell count(RBC),hematocrit(Hct),serum ferritin content,hemoglobin(Hb)compliance rate,and Hb eficiency were compared between the two groups.Results:There was no significant difference in the incidence of adverse reactions such as hyperkalemia,nausea and vomiting,dizziness and diarrhea between the two groups(P>0.05).The levels of RBC,Hct and serum ferritin in the roxadustat group were higher than those in the control group(P<0.05).After 2 months of treatment,the Hb compliance rate and Hb effective rate in the roxadustat group were 98.00%and 100.00%,respectively,which were higher than 85.71%and 85.71%in the control group(P<0.05).Conclusion:Roxadustat combined with erythropoietin has good safety in the treatment of renal anemia.It can improve the RBC and Hct of patients,increase the serum ferritin content of patients,and improve the Hb compliance rate and Hb efficiency.
作者
李娜
郑凝
LI Na;ZHENG Ning(Hemodialysis Room,Tianjin Beichen Hospital,Tianjin 300400,China)
出处
《中国药物滥用防治杂志》
CAS
2024年第7期1292-1294,1307,共4页
Chinese Journal of Drug Abuse Prevention and Treatment
